Lawyers for a certified class of investors in Juno Therapeutics have announced a $24 million settlement to resolve claims that the biopharmaceutical company’s failure to disclose the death of one of its immunotherapy patients led to a 30 percent drop in its share price. Continue reading “Juno Therapeutics Settles Securities Class Action for $24 Million”
Menu